<p>Insmed, Inc.（纳斯达克代码：INSM - 获取免费报告）周二的股价上涨了 7.2%。该公司的股价最高达到 110.50 美元，最后交易价为 111.40 美元。在午盘交易中，共成交 647,989 股，较平均交易量 2,571,582 股下降了 75%。该股票此前收盘价为 103.89 美元。</p>
<h2>Insmed 新闻汇总</h2>
<ul>
<li>罗素重平衡：3 只股票准备上涨</li>
</ul>
<p>以下是本周影响 Insmed 的主要新闻：</p>
<ul>
<li>积极情绪：HC Wainwright 上调了 Insmed 2026 年第二季度每股收益（EPS）预期，表明该业务的短期前景略有改善。</li>
<li>积极情绪：该公司还上调了 2026 财年的每股收益预期，并维持买入评级，增强了对 Insmed 长期增长故事的信心。</li>
<li>中性情绪：HC Wainwright 适度上调了 2026 年第三季度的预期，这是另一个支持性的增量改善，但并非变革性。</li>
<li>中性情绪：Insmed 最近的季度业绩超出了收入和盈利预期，但公司仍在亏损，负利润率使得情绪保持混合。</li>
<li>消极情绪：HC Wainwright 下调了一些长期的每股收益预期，包括 2027 财年至 2030 财年，暗示盈利能力的提升可能比之前预期的要慢。</li>
</ul>
<h2>华尔街分析师预测增长</h2>
<p>几位股票分析师最近对 INSM 股票发表了看法。瑞穗证券在 3 月 25 日的研究报告中将 Insmed 的目标价从 204.00 美元上调至 206.00 美元，并给予该股票 “跑赢大盘” 的评级。巴克莱在 4 月 1 日的报告中将 Insmed 的目标价从 231.00 美元上调至 237.00 美元，并给予该公司 “增持” 评级。Roth Mkm 在 4 月 17 日的研究报告中重申了 “买入” 评级，并设定了 212.00 美元的目标价。Raymond James Financial 在 4 月 10 日的研究报告中开始覆盖 Insmed 股票，设定了 “跑赢大盘” 评级和 200.00 美元的目标价。最后，Truist Financial 在 1 月 12 日的研究报告中设定了 205.00 美元的目标价。目前，两位投资分析师对该股票给予了强烈买入评级，22 位给予了买入评级，1 位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，共识目标价为 211.86 美元。</p>
<ul>
<li>股票轮换正在进行中：以下是未来的赢家</li>
</ul>
<p><strong>查看我们对 INSM 的最新分析</strong></p>
<h2>Insmed 上涨 8.3%</h2>
<p>该公司的市值为 243.8 亿美元，市盈率为-19.58，贝塔值为 0.89。公司的债务与股本比率为 0.80，速动比率为 4.10，流动比率为 4.47。该公司的 50 日移动平均线为 144.00 美元，200 日移动平均线为 164.56 美元。</p>
<p>Insmed（纳斯达克代码：INSM - 获取免费报告）最近于 5 月 7 日发布了季度财报。这家生物制药公司报告的季度每股收益为（0.76 美元），超出分析师一致预期的（0.90 美元）0.14 美元。该季度的收入为 3.0596 亿美元，而分析师预期为 3.0081 亿美元。Insmed 的股本回报率为-130.11%，净利润率为-144.44%。与去年同期相比，Insmed 的季度收入增长了 229.7%。在去年同期，该公司每股收益为（1.42 美元）。股票研究分析师预计 Insmed, Inc.在本年度将发布-2.41 的每股收益。</p>
<h2>Insmed 内部活动</h2>
<p>在相关消息中，内部人士 Michael Alexander Smith 于 3 月 30 日星期一出售了 19,638 股 Insmed 股票。该股票以平均价格 150.98 美元出售，总交易额为 2,964,945.24 美元。出售后，该内部人士持有公司股票 51,871 股，价值 7,831,483.58 美元。此次交易使其持股减少了 27.46%。该交易已在 SEC 的备案中披露，可通过 SEC 网站访问。此外，首席执行官 William Lewis 于 4 月 16 日星期四出售了 10,699 股公司股票。该股票以平均价格 143.97 美元出售，总交易额为 1,540,335.03 美元。交易完成后，首席执行官直接持有公司股票 301,185 股，价值约 43,361,604.45 美元。此次交易使其持股减少了 3.43%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士共出售了 161,193 股公司股票，价值 25,462,012 美元。公司内部人士持有公司股票的 2.10%。</p>
<h2>机构投资者对 Insmed 的看法</h2>
<p>对冲基金和其他机构投资者最近买卖了该公司的股票。CIBC 私人财富集团在第三季度将其在 Insmed 的持股增加了 42.1%。CIBC 私人财富集团目前持有 179 股生物制药公司的股票，价值 26,000 美元，此前在上个季度又购买了 53 股。CoreCap Advisors 在第四季度收购了 Insmed 的新股份，价值 27,000 美元。Stone House Investment Management 在第三季度购买了 Insmed 的新股份，价值 29,000 美元。SBI 证券有限公司在第三季度将其在 Insmed 的持股增加了 404.9%。SBI 证券有限公司目前持有 207 股生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 166 股。最后，GraniteShares Advisors 在第四季度收购了 Insmed 的新股份，价值约 30,000 美元。</p>
<h2>关于 Insmed</h2>
<p>（获取免费报告）</p>
<p>Insmed Incorporated 是一家生物制药公司，专注于开发和商业化针对罕见和严重疾病患者的治疗方案，特别强调难以治疗的肺部感染。公司总部位于新泽西州的布里奇沃特，集中研发针对性药物递送技术和新型制剂，旨在改善治疗选择有限患者的临床结果。</p>
<p>该公司的主要市场产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），这是一种经美国批准的抗生素阿米卡星的吸入脂质体制剂。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Insmed 更好的股票</li>
<li>Shake Shack 股票因财报失利而受到冲击</li>
<li>On Holdings 为马拉松式反弹做好准备：新高即将到来</li>
<li>DRAM 市场动荡：三星失足，Micron 追逐 1000 美元</li>
<li>MP Materials 正在悄然建立稀土强国</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Insmed 吗？</h2>
<p>在考虑 Insmed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Insmed 并不在名单上。</p>
<p>虽然 Insmed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

INSM

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

<p>Insmed（纳斯达克代码：INSM）股价上涨 7.2%，至 111.40 美元，尽管交易量下降了 75%。分析师们的看法不一；HC Wainwright 上调了 2026 年第二季度每股收益（EPS）预期，同时下调了长期预测。瑞穗证券和巴克莱提高了目标价格，市场一致评级为 “买入”，目标价格为 211.86 美元。Insmed 报告的季度每股收益为（0.76 美元），超出预期，收入同比增长 229.7%。公司内部人士的卖出活动引起关注，部分高管出售了大量股份。该公司的市值为 243.8 亿美元，市盈率为负 19.58</p>

<p>Insmed, Inc. (NASDAQ:INSM - Get Free Report)'s stock price shot up 7.2% during trading on Tuesday . The company traded as high as $110.50 and last traded at $111.40. 647,989 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 2,571,582 shares. The stock had previously closed at $103.89.</p>
<div class="lb-trans"><p>Insmed, Inc.（纳斯达克代码：INSM - 获取免费报告）周二的股价上涨了 7.2%。该公司的股价最高达到 110.50 美元，最后交易价为 111.40 美元。在午盘交易中，共成交 647,989 股，较平均交易量 2,571,582 股下降了 75%。该股票此前收盘价为 103.89 美元。</p>
</div><h2>Insmed News Roundup</h2>
<div class="lb-trans"><h2>Insmed 新闻汇总</h2>
</div><ul>
<li>Russell Rebalance: 3 Stocks Ready to Move Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>罗素重平衡：3 只股票准备上涨</li>
</ul>
</div><p>Here are the key news stories impacting Insmed this week:</p>
<div class="lb-trans"><p>以下是本周影响 Insmed 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright raised its Q2 2026 EPS estimate for Insmed, signaling a slightly better near-term outlook for the business.</li>
<li>Positive Sentiment: The firm also increased its FY2026 EPS estimate and maintained a Buy rating, reinforcing confidence in Insmed’s longer-term growth story.</li>
<li>Neutral Sentiment: HC Wainwright modestly raised its Q3 2026 estimate, another incremental improvement that is supportive but not transformative.</li>
<li>Neutral Sentiment: Insmed’s recent quarterly results beat revenue and earnings expectations, but the company is still posting losses and negative margins, which keeps sentiment mixed.</li>
<li>Negative Sentiment: HC Wainwright lowered some longer-dated EPS estimates, including FY2027 through FY2030, suggesting the profitability ramp may be slower than previously expected.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 上调了 Insmed 2026 年第二季度每股收益（EPS）预期，表明该业务的短期前景略有改善。</li>
<li>积极情绪：该公司还上调了 2026 财年的每股收益预期，并维持买入评级，增强了对 Insmed 长期增长故事的信心。</li>
<li>中性情绪：HC Wainwright 适度上调了 2026 年第三季度的预期，这是另一个支持性的增量改善，但并非变革性。</li>
<li>中性情绪：Insmed 最近的季度业绩超出了收入和盈利预期，但公司仍在亏损，负利润率使得情绪保持混合。</li>
<li>消极情绪：HC Wainwright 下调了一些长期的每股收益预期，包括 2027 财年至 2030 财年，暗示盈利能力的提升可能比之前预期的要慢。</li>
</ul>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities analysts recently weighed in on INSM shares. Mizuho increased their target price on Insmed from $204.00 to $206.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, March 25th. Barclays boosted their target price on shares of Insmed from $231.00 to $237.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, April 1st. Roth Mkm reaffirmed a &#34;buy&#34; rating and set a $212.00 price target on shares of Insmed in a research report on Friday, April 17th. Raymond James Financial began coverage on shares of Insmed in a research note on Friday, April 10th. They set an &#34;outperform&#34; rating and a $200.00 price objective for the company. Finally, Truist Financial set a $205.00 target price on Insmed in a research report on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $211.86.</p>
<div class="lb-trans"><p>几位股票分析师最近对 INSM 股票发表了看法。瑞穗证券在 3 月 25 日的研究报告中将 Insmed 的目标价从 204.00 美元上调至 206.00 美元，并给予该股票 “跑赢大盘” 的评级。巴克莱在 4 月 1 日的报告中将 Insmed 的目标价从 231.00 美元上调至 237.00 美元，并给予该公司 “增持” 评级。Roth Mkm 在 4 月 17 日的研究报告中重申了 “买入” 评级，并设定了 212.00 美元的目标价。Raymond James Financial 在 4 月 10 日的研究报告中开始覆盖 Insmed 股票，设定了 “跑赢大盘” 评级和 200.00 美元的目标价。最后，Truist Financial 在 1 月 12 日的研究报告中设定了 205.00 美元的目标价。目前，两位投资分析师对该股票给予了强烈买入评级，22 位给予了买入评级，1 位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，共识目标价为 211.86 美元。</p>
</div><ul>
<li>Stock Rotation is Underway: Here are the Winners Moving Forward</li>
</ul>
<div class="lb-trans"><ul>
<li>股票轮换正在进行中：以下是未来的赢家</li>
</ul>
</div><p><strong>View Our Latest Analysis on INSM</strong></p>
<div class="lb-trans"><p><strong>查看我们对 INSM 的最新分析</strong></p>
</div><h2>Insmed Trading Up 8.3%</h2>
<div class="lb-trans"><h2>Insmed 上涨 8.3%</h2>
</div><p>The firm has a market capitalization of $24.38 billion, a PE ratio of -19.58 and a beta of 0.89. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The firm has a fifty day moving average of $144.00 and a 200 day moving average of $164.56.</p>
<div class="lb-trans"><p>该公司的市值为 243.8 亿美元，市盈率为-19.58，贝塔值为 0.89。公司的债务与股本比率为 0.80，速动比率为 4.10，流动比率为 4.47。该公司的 50 日移动平均线为 144.00 美元，200 日移动平均线为 164.56 美元。</p>
</div><p>Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to analysts' expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.Insmed's quarterly revenue was up 229.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.42) EPS. Equities research analysts expect that Insmed, Inc. will post -2.41 EPS for the current year.</p>
<div class="lb-trans"><p>Insmed（纳斯达克代码：INSM - 获取免费报告）最近于 5 月 7 日发布了季度财报。这家生物制药公司报告的季度每股收益为（0.76 美元），超出分析师一致预期的（0.90 美元）0.14 美元。该季度的收入为 3.0596 亿美元，而分析师预期为 3.0081 亿美元。Insmed 的股本回报率为-130.11%，净利润率为-144.44%。与去年同期相比，Insmed 的季度收入增长了 229.7%。在去年同期，该公司每股收益为（1.42 美元）。股票研究分析师预计 Insmed, Inc.在本年度将发布-2.41 的每股收益。</p>
</div><h2>Insider Activity at Insmed</h2>
<div class="lb-trans"><h2>Insmed 内部活动</h2>
</div><p>In related news, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the sale, the insider owned 51,871 shares of the company's stock, valued at $7,831,483.58. The trade was a 27.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO William Lewis sold 10,699 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares of the company's stock, valued at approximately $43,361,604.45. The trade was a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 161,193 shares of company stock valued at $25,462,012. Corporate insiders own 2.10% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Michael Alexander Smith 于 3 月 30 日星期一出售了 19,638 股 Insmed 股票。该股票以平均价格 150.98 美元出售，总交易额为 2,964,945.24 美元。出售后，该内部人士持有公司股票 51,871 股，价值 7,831,483.58 美元。此次交易使其持股减少了 27.46%。该交易已在 SEC 的备案中披露，可通过 SEC 网站访问。此外，首席执行官 William Lewis 于 4 月 16 日星期四出售了 10,699 股公司股票。该股票以平均价格 143.97 美元出售，总交易额为 1,540,335.03 美元。交易完成后，首席执行官直接持有公司股票 301,185 股，价值约 43,361,604.45 美元。此次交易使其持股减少了 3.43%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士共出售了 161,193 股公司股票，价值 25,462,012 美元。公司内部人士持有公司股票的 2.10%。</p>
</div><h2>Institutional Investors Weigh In On Insmed</h2>
<div class="lb-trans"><h2>机构投资者对 Insmed 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC boosted its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new stake in Insmed in the fourth quarter valued at $27,000. Stone House Investment Management LLC bought a new position in Insmed during the 3rd quarter valued at $29,000. SBI Securities Co. Ltd. grew its holdings in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 166 shares in the last quarter. Finally, GraniteShares Advisors LLC acquired a new stake in shares of Insmed in the 4th quarter valued at about $30,000.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买卖了该公司的股票。CIBC 私人财富集团在第三季度将其在 Insmed 的持股增加了 42.1%。CIBC 私人财富集团目前持有 179 股生物制药公司的股票，价值 26,000 美元，此前在上个季度又购买了 53 股。CoreCap Advisors 在第四季度收购了 Insmed 的新股份，价值 27,000 美元。Stone House Investment Management 在第三季度购买了 Insmed 的新股份，价值 29,000 美元。SBI 证券有限公司在第三季度将其在 Insmed 的持股增加了 404.9%。SBI 证券有限公司目前持有 207 股生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 166 股。最后，GraniteShares Advisors 在第四季度收购了 Insmed 的新股份，价值约 30,000 美元。</p>
</div><h2>About Insmed</h2>
<div class="lb-trans"><h2>关于 Insmed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.</p>
<div class="lb-trans"><p>Insmed Incorporated 是一家生物制药公司，专注于开发和商业化针对罕见和严重疾病患者的治疗方案，特别强调难以治疗的肺部感染。公司总部位于新泽西州的布里奇沃特，集中研发针对性药物递送技术和新型制剂，旨在改善治疗选择有限患者的临床结果。</p>
</div><p>The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.</p>
<div class="lb-trans"><p>该公司的主要市场产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），这是一种经美国批准的抗生素阿米卡星的吸入脂质体制剂。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Insmed</li>
<li>Shake Shack Stock Gets Shaken After Earnings Miss</li>
<li>On Holdings Sets Up for Marathon Rally: New Highs Are Coming</li>
<li>The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000</li>
<li>MP Materials Is Quietly Building a Rare Earth Powerhouse</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Insmed 更好的股票</li>
<li>Shake Shack 股票因财报失利而受到冲击</li>
<li>On Holdings 为马拉松式反弹做好准备：新高即将到来</li>
<li>DRAM 市场动荡：三星失足，Micron 追逐 1000 美元</li>
<li>MP Materials 正在悄然建立稀土强国</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Insmed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Insmed 吗？</h2>
</div><p>Before you consider Insmed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insmed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Insmed 并不在名单上。</p>
</div><p>While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insmed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insmed (NASDAQ:INSM) Shares Up 7.2%  - What's Next?

Market Beat

Insmed

Insmed (NASDAQ:INSM) 股价上涨 7.2% - 接下来会发生什么？